top of page
Buscar

European Commission approves extended Libtayo dosing interval across existing cancer indications

Foto do escritor: nuaxia
nuaxia
há 3 horas
2 min de leitura

The European Commission has approved a longer dosing interval for Regeneron's Libtayo across its existing authorised cancer indications, offering an alternative administration schedule without expanding the medicine's approved disease indications.


Regeneron announced on 17 November 2026 that the European Commission had authorised an alternative dosing regimen for Libtayo (cemiplimab) across its existing approved skin, lung and cervical cancer indications, allowing eligible patients to receive 700 mg intravenously every six weeks after an initial 12 weeks of 350 mg every three weeks.


The decision also permits shorter infusion times for selected 350 mg doses following a well-tolerated initial infusion, potentially reducing treatment visits and administration burden; this is an EU dosing and administration update rather than approval for a new cancer indication, while the corresponding US supplemental application remains under FDA review.

Field

Content

Company

Regeneron

Medicine

Libtayo (cemiplimab)

Regulatory Authority

European Commission

Approval Date

17 November 2026

Approval Type

Alternative dosing and administration authorisation

Therapeutic Area

Oncology

Existing Indication Areas

Authorised skin lung and cervical cancer indications

Initial Dosing

350 mg intravenously every three weeks

Initial Dosing Duration

12 weeks

Alternative Maintenance Dose

700 mg intravenously

Alternative Dosing Interval

Every six weeks

Administration Update

Shorter infusion times permitted for selected 350 mg doses following a well-tolerated initial infusion

New Cancer Indication

No

Potential Patient Benefit

Fewer infusion visits and reduced administration burden for eligible patients

EU Regulatory Status

Approved alternative regimen

US Regulatory Status

Corresponding supplemental application under FDA review

Primary Source

https://investor.regeneron.com/news-releases/news-release-details/libtayor-cemiplimab-approved-european-union-eu-extended-dosing/


Discover how nuaxia can support your next medical education initiative:

 
 
 

Comentários

Avaliado com 0 de 5 estrelas.
Ainda sem avaliações

Adicione uma avaliação
bottom of page